ArticleScientific reports2025
Pulsed electromagnetic field stimulation subtly modulates doxorubicin sensitivity in a spheroid co-culture model of osteosarcoma.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulsed electromagnetic fields induce ferroptosis in osteosarcoma cells and promote osteogenic differentiation.Journal of bone oncology · 2026Article
- Stemness-associated MEF-derived extruded nanovesicles cooperate withNanoscale advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Osteosarcoma is a rare but aggressive bone cancer primarily affecting children and adolescents. Current treatment options are limited by toxicity and reduced efficacy in advanced stages. Pulsed electromagnetic field (PEMF) stimulation has shown promise as a non-invasive anticancer strategy, though inconsistent experimental models and exposure protocols limit translational progress. In the present study, a co-culture spheroid model of osteosarcoma was optimized using human osteosarcoma U2OS cells and bone marrow-derived mesenchymal stem cells (hBMSCs) and used to investigate whether PEMF exposure (1.5 mT, 75 Hz, sinusoidal) enhances spheroid sensitivity to doxorubicin (DOX). The model was characterized by structural integrity, mechanical properties, and functionality: while U2OS monoculture spheroids lacked structural stability, 1:3 MSC-U2OS co-cultures produced compact, stiff spheroids with migratory potential. PEMF stimulation for 3 days at 4 h per day reduced cell metabolic activity and spheroid stiffness and caused the downregulation of several genes associated with proliferation, survival, and invasion. These changes were most evident when combined with low-dose DOX, suggesting altered sensitivity; however, the effect was not uniformly detectable across all assessment methods. Thus, PEMF stimulation induces biological changes consistent with increased chemosensitivity in a subset of conditions, though the effect is subtle and assay-dependent. The developed co-culture model offers a relevant platform for further investigation of PEMF as a modulator of anticancer treatment response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.